Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders

Nate Shepard,David Baez-Nieto,Sumaiya Iqbal,Erkin Kurganov,Nikita Budnik,Arthur J. Campbell,Jen Q. Pan,Morgan Sheng,Zohreh Farsi

DOI: https://doi.org/10.1038/s41598-024-53102-3

IF: 4.6

2024-02-03

Scientific Reports

Abstract:Human genetic studies have revealed rare missense and protein-truncating variants in GRIN2A , encoding for the GluN2A subunit of the NMDA receptors, that confer significant risk for schizophrenia (SCZ). Mutations in GRIN2A are also associated with epilepsy and developmental delay/intellectual disability (DD/ID). However, it remains enigmatic how alterations to the same protein can result in diverse clinical phenotypes. Here, we performed functional characterization of human GluN1/GluN2A heteromeric NMDA receptors that contain SCZ-linked GluN2A variants, and compared them to NMDA receptors with GluN2A variants associated with epilepsy or DD/ID. Our findings demonstrate that SCZ-associated GRIN2A variants were predominantly loss-of-function (LoF), whereas epilepsy and DD/ID-associated variants resulted in both gain- and loss-of-function phenotypes. We additionally show that M653I and S809R, LoF GRIN2A variants associated with DD/ID, exert a dominant-negative effect when co-expressed with a wild-type GluN2A, whereas E58Ter and Y698C, SCZ-linked LoF variants, and A727T, an epilepsy-linked LoF variant, do not. These data offer a potential mechanism by which SCZ/epilepsy and DD/ID-linked variants can cause different effects on receptor function and therefore result in divergent pathological outcomes.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand how GRIN2A gene mutations associated with schizophrenia (SCZ), epilepsy, and developmental delay/intellectual disability (DD/ID) lead to different clinical phenotypes. Specifically, researchers explored the effects of these mutations on NMDA receptors (NMDARs) through functional analysis, especially whether these mutations would lead to loss - of - function (LoF) or gain - of - function (GoF) of the receptors, and whether they showed a dominant - negative effect when co - expressed with wild - type GRIN2A. ### Main Findings 1. **Schizophrenia - related mutations**: - Most SCZ - related GRIN2A mutations showed loss - of - function (LoF). In particular, protein - truncating variants (PTVs) in the N - terminal half completely lost their response to glutamate. - Some missense mutations (such as Q811P and Y698C) also showed LoF, but not as severely as PTVs. 2. **Epilepsy - and DD/ID - related mutations**: - These mutations included both loss - of - function (LoF) and gain - of - function (GoF). - In particular, the two DD/ID - related LoF mutations, M653I and S809R, showed a dominant - negative effect when co - expressed with wild - type GRIN2A, while SCZ - and epilepsy - related LoF mutations did not have this effect. 3. **Dominant - negative effect**: - The study found that the DD/ID - related M653I and S809R mutations, when co - expressed with wild - type GRIN2A, significantly reduced the function of NMDA receptors, which may be one of the mechanisms leading to more severe pathological phenotypes. ### Conclusion These data reveal a potential mechanism that the same GRIN2A mutations may lead to different receptor function changes in different situations, thus resulting in different pathological outcomes. In particular, the presence of the dominant - negative effect may explain why some mutations in the heterozygous state lead to more severe disease phenotypes, such as DD/ID, while other mutations mainly lead to milder phenotypes, such as SCZ or epilepsy. ### Significance This study not only helps to understand the relationship between GRIN2A mutations and different neurodevelopmental and mental disorders, but also provides a theoretical basis for the future development of drugs targeting NMDA receptor dysfunction.

Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders

Heterogeneous Clinical and Functional Features of GRIN2D-related Developmental and Epileptic Encephalopathy.

Significant Linkage and Association Between a Functional (gt)n Polymorphism in Promoter of the N-methyl-D-aspartate Receptor Subunit Gene (GRIN2A) and Schizophrenia.

N-terminal alternative splicing of GluN1 regulates the maturation of excitatory synapses and seizure susceptibility.

GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms

GRIN2A Variants Associated with Idiopathic Generalized Epilepsies.

Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology

A De Novo Loss-of-function GRIN2A Mutation Associated with Childhood Focal Epilepsy and Acquired Epileptic Aphasia.

Molecular Insights into the Role of Pathogenic Nssnps in GRIN2B Gene Provoking Neurodevelopmental Disorders

Grin1 Y 647 S/+ Mice: A Preclinical Model of GRIN1 -Related Neurodevelopmental Disorder

Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties

GRIN2B disease-associated mutations disrupt the function of BK channels and NMDA receptor signalling nanodomains

Clinical and Therapeutic Significance of Genetic Variation in the GRIN Gene Family Encoding NMDARs

Grin1Y647S/+ Mice: A Preclinical Model of GRIN1-Related Neurodevelopmental Disorder

De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor

De novo GRIN2A variants associated with epilepsy and autism and literature review

Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy

Characterization of Mice Carrying a Neurodevelopmental Disease-Associated GluN2B(L825V) Variant

De Novo Mutations and Rare Variants Occurring in NMDA Receptors.

Functional Investigation of a GRIN2A Variant Associated with Rolandic Epilepsy

Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors